TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
  • News & Media
    • Press Releases
    • Media & Articles
    • Theralink Blog
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • Conference Abstracts
    • FAQ
  • Investor Relations
    • Market Opportunity
    • Investor Relations Email Alerts
    • Company Information
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Contact
    • Investors Relations FAQ
  • Contacts

Investor Relations

Theralink   →  Investor Relations

Investor Relations

INVESTOR RELATIONS

Company Overview

Theralink Technologies provides personalized medicine data through its Theralink assays, initially for breast cancer, to assist the treating physician in a data-driven process for treatment decision support and potentially enable new predictive biomarker-based patient selection. Theralink is the leading developer of phosphoproteomic technologies for measuring the activation state of key drug targets and signaling pathways, with applications across multiple cancer types, including breast, non-small cell lung, ovarian, liver, prostate, gastric, brain, kidney, colorectal and pancreatic. Theralink was developed to empower physicians with potentially actionable information missed entirely by genomics assays to help them make time-sensitive treatment decisions for their patients. Theralink was designed to provide new predictive biomarkers through the direct measurement of drug target activation mapping, making Theralink instrumental in the development of molecular targeted therapies. The information gathered through measurement of protein and phosphoprotein markers has the potential to help physicians make molecularly rationalized treatment decisions that could improve treatment outcomes and reduce side effects by foregoing ineffective therapy.

Contact Information

Investor Relations

KCSA Strategic Communications
Valter Pinto and Allison Soss
420 Fifth Avenue New York NY 10018
T: (212) 896-1254
investors@theralink.com

INVESTOR RELATIONS

  • Overview
  • Press Releases
  • Events & Presentations
  • Financial Information
  • Stock Information
  • Investor Resources
    • FAQ
    • Contact Us
  • Corporate Governance
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
Copyright © 2022 Theralink. All rights reserved.